Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 250 participants.

Also called NCT04591392

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
atHeart Medical (from the registry)
Registry
  • NCT NCT04591392
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, France, Switzerland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04591392. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-12 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
Acronym
ASCENT ASD
Condition
Heart Septal Defect
Condition
Heart Septal Defects, Atrial
Condition
Heart Defects, Congenital
Condition
Cardiovascular Abnormalities
Condition
Cardiovascular Diseases
Condition
Heart Diseases
Condition
Congenital Abnormalities
Intervention (Device)
reSept ASD Occluder
Lead sponsor
atHeart Medical (class: industry)

Record details

Record id
cardio:ct-nct04591392
Content hash
f2b5b76708875060cda3bf32c02b7c317f328dfe32bc0bbde4efc14a717bd011